SURVYR
13F +9% · EVERPOINT Institutional Filing Alert

EverPoint Asset Management (Point72 Arm) (Point72 Fundamental L/S Sub-Advisor) added to ISRG (+9% shares QoQ · 15.5% of 13F portfolio)

Form 13F-HR institutional holdings disclosure · Filed 2026-10-16

EverPoint Holdings › All Filing Alerts › SEC Filing ↗

ISRG

Intuitive Surgical, Inc.
$451.63
−$0.66 (0.15%)Oct 26 close
Health CareS&P 500 CompareTechnicals
Model valuationRoughly fairly valuedDCF base $485
1M3M6M1Y2Y
-40%-27%-13%+1%+15%Oct 2025Oct 2026Apr 202652w high $603.8852w low $328.57
ISRGSPY
Wall St. Highest PT $685.00 (+51.7%) Wall St. Avg PT $480.17 (+6.3%)
$332$457$582$707$831POC $397Hi $685Avg $480
Underwater Drawdown %Max DD -44.0%Current -23.8%
0.0%-44.0%
Relative Strength vs SPY-31.0% vs SPYUnderperforming
+57%0%-57%
1W
+$18.45 (4.26%)
1M
+$46.45 (11.46%)
3M
+$94.80 (26.57%)
6M
−$19.36 (4.11%)
YTD
−$114.73 (20.26%)
1Y
−$94.88 (17.36%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
30 analysts · mean score 1.76
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$451.63
Average target$480.17
+$28.54 (+6.3%) upsideaverage target vs current price
CurrentAverageMedian
Low$324.00
Median$480.17
High$685.00
12-month Wall Street target range

Third-party ratings, not SURVYR.'s views.

Health check

Financial health
DistressGrey zoneSafe
Safe zone
Altman Z-score 29.9
Above 2.99 is the safe zone, below 1.81 the distress zone.
Quality
WeakAverageStrong
Strong
Piotroski F-score 8 of 9
See the tests
  • ✓Positive net income
  • ✓Positive operating cash flow
  • ✓Return on assets improved
  • ✓Cash flow above net income
  • ✓Long-term debt / assets fell
  • ✓Current ratio improved
  • ✓No share dilution
  • ✗Gross margin improved
  • ✓Asset turnover improved

Computed by SURVYR. from the company's SEC filings (latest balance sheet Sep 30, 2026). Descriptive, not a forecast.

Key stats & company

Market value$151.2B
P/E (last 12 months)51.8
P/E (next 12 months, estimated)34.6
52-week range$328.57 – $603.88
Revenue growth (latest quarter vs a year ago)+21.7%
Dividend yieldNo dividend
Analyst consensusBuy (30)
Average analyst price target$480.17 (+6%)

What they do

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. It offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach.

Healthcare · Medical Instruments & Supplies
Valuation and fundamentals

Valuation & fundamentals

Bottom line
Roughly fairly valued
Model read-out from the numbers below, not advice. Score +0 (DCF counts double).
•DCF (base case)above the price by 7%
▼Forward P/E vs sector34.6x vs median 18.0x
▲Piotroski F-score8/9
▲Altman Z29.9 (safe)
▲Net debt / EBITDA-1.2x
•Analyst target+6% (30 analysts)

Discounted cash flow

Bear
$267
-41%
growth 12% · disc. 10.2% · term. 2.0%
Base
$485
+7%
growth 20% · disc. 9.2% · term. 2.5%
Bull
$806
+78%
growth 24% · disc. 8.2% · term. 3.0%

A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.

Reverse DCFfor context, not a signal
Today's price assumes free cash flow grows about 14% a year for 10 years.
Implied
+14%/yr
FCF, last 3 yrs
+27%/yr
FCF, last 5 yrs
+15%/yr
Revenue, last 3 yrs
+17%/yr
Revenue, last 5 yrs
+18%/yr
Same inputs as the DCF above: trailing free cash flow 4.1B, 9.2% discount rate, 2.5% growth after year 10, net cash and today's share count. Actual growth rates are compound annual rates from SEC annual filings through FY2025; "n/a" means too little history or a negative starting year.
Edit assumptions · recalculates instantly
Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-09-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.00 (n/a) × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs Health Care

P/E (trailing)
sector median 31.2× · 81st pct
 51.8×
pricier
Forward P/E
sector median 18.0× · 88th pct
 34.6×
pricier
EV / EBITDA
sector median 16.2× · 95th pct
 44.8×
pricier
Price / sales
sector median 3.3× · 92nd pct
 13.1×
pricier
Price / book
sector median 3.5× · 86th pct
 9.5×
pricier
FCF yield
sector median 4.0% · 33rd pct
 2.7%
pricier

Forward EPS $12.39 vs trailing $8.27 (+50% expected growth). Forward P/E uses analysts' next-12-month estimate.

Backlog (remaining performance obligations)

RPO
$1.7B
as of 2021-09-30
vs a year ago
+14%
YoY
× TTM revenue
0.15×
coverage
19-06
19-09
20-03
20-06
20-09
21-03
21-06
21-09

Contracted revenue not yet recognized, from SEC filings (XBRL tag RevenueRemainingPerformanceObligation).

Quality & financial health

Gross margin
67.2%
Operating margin
28.4%
FCF margin
35.3%
Net margin
25.5%
Return on equity
18.5%
Return on invested capital
22.6%
Net debt / EBITDA
-1.2×
Current ratio
3.3×
Interest cover
–
Cash conversion (OCF/NI)
1.4×
Piotroski F-score 8/9 · last two fiscal years
✓ Positive net income✓ Positive operating cash flow✓ Return on assets improved✓ Cash flow above net income✓ Long-term debt / assets fell✓ Current ratio improved✓ No share dilution✗ Gross margin improved✓ Asset turnover improved

Altman Z-score 29.9 (safe zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.

Analysts

Mean target
$480
+6%
Analysts
30
Buy
Range
$324–$685
low – high
● price · ◆ mean target

Annual history

FYRevenueNet incomeFree cash flow
2025$10.1B$2.9B$3.0B
2024$8.4B$2.3B$2.4B
2023$7.1B$1.8B$1.8B
2022$6.2B$1.3B$1.5B
2021$5.7B$1.7B$2.1B
2020$4.4B$1.1B$1.5B

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +17.4%.

For information only · Important disclosures

Grades vs sector

Momentum
11th percentile in sector
D-
12-1 return: -23.9%
Percentile within its GICS sector across the S&P 1500.
Growth
78th percentile in sector
B+
Revenue growth (YoY): +18.5%
Percentile within its GICS sector across the S&P 1500.
Value
11th percentile in sector
D-
Forward E/P: 2.8% · EBITDA/EV: 2.9%
Percentile within its GICS sector across the S&P 1500.
Profitability
80th percentile in sector
B+
Profit margin: +28.4% · Return on equity: +17.4%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
ranked 425 of 499 · 12-month momentum -15.7%
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

ISRG earningsReported Oct 20, 2026▲ Above estimates
Results · After the close
EPS actual$3.00
EPS estimate$2.64
Surprise+13.6%
RevenueNot in our data yet

Revenue for this quarter is not in our data yet. It arrives with the quarterly filing.

Next report
Thu Jan 21, 2027Time not confirmed
EPS consensus$2.95
Revenue consensus–
Last 4 quarters · EPS vs estimate
Oct 20, 2026$3.00est $2.64+13.6%Above estimates
Jul 16, 2026$2.80est $2.50+11.9%Above estimates
Apr 21, 2026$2.50est $2.11+18.7%Above estimates
Jan 22, 2026$2.53est $2.27+11.6%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-26 18:07:29 ET
25-0125-0425-0725-1026-0126-0426-0726-100.003.00
EstimateActual (beat)Actual (miss)

News & catalysts

More news
2 unpopular stocks that deserve a second chance and 1 that underwhelm
StockStory · 2h ago
Gemini Latest Stock Portfolio: Top 4 Stock Picks
Insider Monkey · Oct 23
Intuitive Surgical earnings analysis: questions answered and next catalysts
Investing.com · Oct 21
Intuitive Surgical: 3 Key Takeaways for Long-Term Investors
Nasdaq · Oct 21
Capital Group Growth (CGGR) Buys $18.3 Million More Amazon on Oct. 19
GuruFocus.com · Oct 21
Insider trades
Widman Fredrik
VP Corporate Controller · 2026-10-23
Sell
$1.8M
Barratt Craig H
Director · 2026-10-23
Sell
$510.4K
Guthart Gary S
Director · 2026-10-23
Sell
$9.1M
Wadors Patricia L
SVP Chief Human Resources Offi · 2026-10-23
Sell
$478.4K
Widman Fredrik
VP Corporate Controller · 2026-09-15
Sell
$203.3K
Widman Fredrik
VP Corporate Controller · 2026-09-15
Sell
$204.4K
Brosius Mark
EVP & Chief Mfg and Supply Cha · 2026-09-11
Sell
$9.1K
Brosius Mark
EVP & Chief Mfg and Supply Cha · 2026-09-10
Sell
$8.0K
Brosius Mark
EVP & Chief Mfg and Supply Cha · 2026-09-09
Sell
$8.1K
Brosius Mark
EVP & Chief Mfg and Supply Cha · 2026-09-08
Sell
$16.6K
Brosius Mark
EVP & Chief Mfg and Supply Cha · 2026-08-21
Sell
$28.9K
Brosius Mark
EVP & Chief Mfg and Supply Cha · 2026-08-20
Sell
$30.5K

Stats refreshed 2026-10-26 18:07:29 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026